Search

mRNA-1283

[L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from

Ioversol

[L41780] Ioversol was approved by the FDA in 1989 and is currently indicated for computed tomographic (CT) imaging and contrast enhancement in peripheral arteriography, coronary arteriography, and left

Encorafenib

encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved

Tebipenem pivoxil

[L57979] The FDA approved tebipenem pivoxil on June 17, 2026, for complicated urinary tract infections including pyelonephritis caused by designated susceptible organisms in adult patients who have

Fructose

Adinazolam

It has never been approved by the FDA for clinical use.

Tocopherol

[A32436] It is currently under the list of substances generally recognized as safe (GRAS) in the FDA for the use of human consumption.[L2114] … They present strong antioxidant activities, and it is determined as the major form of vitamin E.

Selinexor

[L10145] The FDA approved Selinexor in June 2019.

Lurbinectedin

[A214331] On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression

Daptomycin

[A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]